Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haemonetics Corporation (NYSE: HAE) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Massachusetts corporation and NYSE-listed issuer, Haemonetics reports material events, financial results and shareholder matters through forms such as Form 8-K.
Recent 8-K filings show several key categories of information. Under Item 2.02, Haemonetics furnishes press releases announcing quarterly financial results, including results for specific fiscal quarters and the first half of a fiscal year. These filings clarify that the furnished earnings releases are not deemed filed for purposes of Section 18 of the Exchange Act but provide investors with detailed financial updates.
Another important filing type is the Item 8.01 Other Events 8-K, such as the report dated January 9, 2026 describing Haemonetics’ acquisition of Vivasure Medical Limited. That filing outlines the terms of the transaction, including upfront consideration, contingent payments based on sales growth and milestone achievements, and the use of available cash on hand to finance the acquisition. It also references the related press release furnished as an exhibit.
Haemonetics’ SEC filings also document shareholder meeting results. An 8-K under Item 5.07 details the outcomes of votes at the 2025 Annual Meeting of Shareholders, including the election of directors, advisory approval of executive compensation and ratification of the independent registered public accounting firm.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can help summarize long documents, highlight key sections and surface items such as earnings disclosures, acquisition terms and shareholder vote results. This allows users to review Haemonetics’ regulatory history, understand significant corporate events and see how the company communicates financial and governance information to the market.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting 0 shares and 0% beneficial ownership of Haemonetics Corp common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries report ownership separately under SEC Release No. 34-39538. The filing is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026.
Haemonetics Corporation disclosure: a group affiliated with North Peak Capital reports beneficial ownership of 2,370,495 shares, equal to 5.1% of common stock based on 46,471,350 shares outstanding as of January 30, 2026.
The filing is a joint Schedule 13G showing that North Peak Capital Management, LLC (investment manager) and related entities and individuals (including North Peak Capital GP, LLC; North Peak Funds; Jeremy S. Kahan; Michael K. Kahan) may be deemed to beneficially own the disclosed shares, with 1,882,037 shares (4.0%) attributable to North Peak Capital GP and the Kahan reporting persons. The filings include specific per‑entity holdings and state the group disclaims direct beneficial ownership beyond the amounts shown.
Haemonetics Corporation has repaid in full its 0.00% Convertible Senior Notes due 2026 at their scheduled maturity. The company paid an aggregate of $300,000,000 in cash, equal to the outstanding principal on the notes, using a combination of cash on hand and borrowings under its revolving credit facility.
No noteholders chose to convert their notes into equity before the cut-off date, so the entire principal was settled in cash rather than shares. The capped call transactions that were entered into when the notes were originally issued have now expired in line with their terms as the notes reached maturity.
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report a passive ownership stake in Haemonetics Corp3,163,104 shares of Haemonetics common stock, representing 6.76% of the class as of 12/31/2025.
The firms report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over all 3,163,104 shares. They certify the position was acquired and is held in the ordinary course of business, not to change or influence control of Haemonetics.
Haemonetics Corporation filed a current report to inform investors that on February 12, 2026, it published its 2024-2025 Corporate Responsibility Report. The report is available in the Corporate Responsibility section of the company’s website, highlighting its disclosure on environmental, social, and governance-related topics.
The company also clarifies that the information shared under this item is being furnished under Regulation FD rather than filed, meaning it is not subject to Section 18 liability of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings.
Haemonetics Corporation reported solid quarterly earnings with softer sales. For the three months ended December 27, 2025, net revenues were $338.97 million, down from $348.54 million a year earlier, while net income increased to $44.74 million from $37.49 million, lifting diluted EPS to $0.95 from $0.74.
For the nine-month period, revenue was $987.68 million versus $1.03 billion, but net income rose to $117.46 million and diluted EPS to $2.46, reflecting stronger gross margins and lower cost of goods sold. Operating cash flow jumped to $222.28 million, supporting acquisitions and share repurchases.
The company continued to reshape its portfolio, completing the Attune Medical and OpSens acquisitions and, subsequent to quarter-end, acquiring Vivasure Medical Limited with $60.7 million paid in cash at closing and potential contingent payments. It also sold its Whole Blood product line for $43.3 million plus contingent consideration and maintained significant leverage through $1.22 billion of total debt, including convertible senior notes due 2026 and 2029.
Haemonetics Corporation filed a current report stating that it issued a press release with financial results for the third quarter and nine months ended December 27, 2025. The press release, dated February 5, 2026, is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.
Haemonetics Corporation has completed the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company developing next-generation technology for percutaneous vessel closure. Haemonetics acquired all outstanding equity interests of Vivasure for €100 million, or approximately €52 million net of certain prior investments, loans and other customary closing adjustments. The agreement also includes up to an additional €85 million in contingent consideration tied to sales growth and other milestones, subject to adjustment for specified prior investments and loan amounts. Haemonetics financed the transaction entirely with available cash on hand.
Haemonetics (HAE) reported an insider share purchase on Form 4. A company director bought 1,400 shares of common stock at $70.56 on 11/10/2025. Following the transaction, the director’s direct beneficial ownership stands at 24,757 shares.
The ownership figure includes unvested restricted stock units that were previously reported. This filing records an open-market purchase by a board member and updates the director’s total holdings.
Haemonetics Corporation reported lower quarterly sales but stronger profitability. For the three months ended September 27, 2025, net revenues were $327.3 million versus $345.5 million a year ago, while gross profit rose to $194.7 million from $187.4 million as cost of goods sold declined. Operating income increased to $58.5 million, and net income was $38.7 million (diluted EPS $0.81) compared with $33.8 million ($0.66) last year.
For the six months ended September 27, 2025, net revenues were $648.7 million versus $681.7 million, and net income was $72.7 million, roughly flat year over year. Operating cash flow strengthened to $128.7 million from $21.4 million, supported by lower inventories and working capital changes.
The company recorded an $8.6 million impairment of certain Hospital business intangibles. It continued portfolio moves: completed the Whole Blood divestiture in January 2025 and executed a new ASR in August 2025, repurchasing $75.0 million of stock (1,430,579 shares at $52.43), leaving $425.0 million authorized under the 2025 program as of September 27, 2025. Shares outstanding were 46,809,672 as of October 31, 2025.